148 related articles for article (PubMed ID: 32440717)
1. ASO Author Reflections: A Nomogram to Predict Recurrence after Curative-Intent Resection for Neuroendocrine Liver Metastasis.
Tsilimigras DI; Xiang JX; Zhang XF; Pawlik TM
Ann Surg Oncol; 2020 Oct; 27(10):3727-3728. PubMed ID: 32440717
[No Abstract] [Full Text] [Related]
2. ASO Author Reflections: Multi-institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma.
Zhang XF; Pawlik TM
Ann Surg Oncol; 2021 Nov; 28(12):7634-7635. PubMed ID: 34027584
[No Abstract] [Full Text] [Related]
3. Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
Ann Surg Oncol; 2020 Oct; 27(10):3717-3726. PubMed ID: 32436187
[TBL] [Abstract][Full Text] [Related]
4. Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group.
Merath K; Bagante F; Beal EW; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha F; Kanji Z; Weber S; Fisher A; Fields R; Krasnick BA; Idrees K; Smith PM; Cho C; Beems M; Schmidt CR; Dillhoff M; Maithel SK; Pawlik TM
J Surg Oncol; 2018 Apr; 117(5):868-878. PubMed ID: 29448303
[TBL] [Abstract][Full Text] [Related]
5. ASO Author Reflections: Pancreatic Neuroendocrine Tumor Recurrence and Survival Predicted by Ki67.
Nieveen van Dijkum EJM
Ann Surg Oncol; 2019 Dec; 26(Suppl 3):531-532. PubMed ID: 30519760
[No Abstract] [Full Text] [Related]
6. Recurrence of Non-functional Pancreatic Neuroendocrine Tumors After Curative Resection: A Tumor Burden-Based Prediction Model.
Dong DH; Zhang XF; Lopez-Aguiar AG; Poultsides G; Rocha F; Weber S; Fields R; Idrees K; Cho C; Maithel SK; Pawlik TM
World J Surg; 2021 Jul; 45(7):2134-2141. PubMed ID: 33768309
[TBL] [Abstract][Full Text] [Related]
7. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome.
Xiang JX; Zhang XF; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Dec; 118(7):1096-1104. PubMed ID: 30261105
[TBL] [Abstract][Full Text] [Related]
8. A Novel Nomogram to Predict the Prognosis of Patients Undergoing Liver Resection for Neuroendocrine Liver Metastasis: an Analysis of the Italian Neuroendocrine Liver Metastasis Database.
Ruzzenente A; Bagante F; Bertuzzo F; Aldrighetti L; Ercolani G; Giuliante F; Ferrero A; Torzilli G; Grazi GL; Ratti F; Cucchetti A; De Rose AM; Russolillo N; Cimino M; Perri P; Cataldo I; Scarpa A; Guglielmi A; Iacono C
J Gastrointest Surg; 2017 Jan; 21(1):41-48. PubMed ID: 27503330
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for short recurrence-free survival after resection of pancreatic neuroendocrine tumor (PanNET) liver metastases: which patients should undergo resection?
Masui T; Nagai K; Anazawa T; Kasai Y; Sato A; Nakano K; Uchida Y; Yogo A; Kawaguchi Y; Takaori K; Uemoto S
Scand J Gastroenterol; 2020 Apr; 55(4):479-484. PubMed ID: 32223573
[No Abstract] [Full Text] [Related]
10. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
[TBL] [Abstract][Full Text] [Related]
11. A retrospective cohort study of pancreatic neuroendocrine tumors at single institution over 15 years: New proposal for low- and high-grade groups, validation of a nomogram for prognosis, and novel follow-up strategy for liver metastases.
Ye L; Ye H; Zhou Q; Li Z; Lin Q; Tan L; Gao W; Fu Z; Zheng S; Chen R
Int J Surg; 2016 May; 29():108-17. PubMed ID: 27000717
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of preoperative peripheral blood neutrophil/lymphocyte ratio for lymph node metastasis in patients of resectable pancreatic neuroendocrine tumors: a nomogram-based study.
Tong Z; Liu L; Zheng Y; Jiang W; Zhao P; Fang W; Wang W
World J Surg Oncol; 2017 May; 15(1):108. PubMed ID: 28558772
[TBL] [Abstract][Full Text] [Related]
13. MRI-based nomogram estimates the risk of recurrence of primary nonmetastatic pancreatic neuroendocrine tumors after curative resection.
Sun HT; Zhang SL; Liu K; Zhou JJ; Wang XX; Shen TT; Song XH; Guo YL; Wang XL
J Magn Reson Imaging; 2019 Aug; 50(2):397-409. PubMed ID: 30589158
[TBL] [Abstract][Full Text] [Related]
14. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study.
Birnbaum DJ; Turrini O; Vigano L; Russolillo N; Autret A; Moutardier V; Capussotti L; Le Treut YP; Delpero JR; Hardwigsen J
Ann Surg Oncol; 2015 Mar; 22(3):1000-7. PubMed ID: 25190116
[TBL] [Abstract][Full Text] [Related]
15. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis.
Zhang XF; Beal EW; Weiss M; Aldrighetti L; Poultsides GA; Bauer TW; Fields RC; Maithel SK; Marques HP; Pawlik TM
J Surg Oncol; 2018 Feb; 117(2):171-181. PubMed ID: 28940257
[TBL] [Abstract][Full Text] [Related]
16. ASO Author Reflections: Elevated Preoperative Specific Growth Rate is Associated with Shortened Survival After Resection for Pancreatic Neuroendocrine Tumors.
Baechle JJ; Marincola Smith P; Idrees K
Ann Surg Oncol; 2020 Oct; 27(10):3924-3925. PubMed ID: 32468347
[No Abstract] [Full Text] [Related]
17. Conditional disease-free survival after curative-intent liver resection for neuroendocrine liver metastasis.
Sahara K; Merath K; Tsilimigras DI; Hyer JM; Guglielmi A; Aldrighetti L; Weiss M; Fields RC; Poultsides GA; Maithel SK; Endo I; Pawlik TM; Other Members Of The U S Neuroendocrine Tumor Study Group
J Surg Oncol; 2019 Dec; 120(7):1087-1095. PubMed ID: 31550406
[TBL] [Abstract][Full Text] [Related]
18. ASO Author Reflections: Can We Evaluate Surgical Quality for Pancreatic Neuroendocrine Tumors?
Fermi F; Partelli S; Falconi M
Ann Surg Oncol; 2024 Jun; 31(6):4117-4118. PubMed ID: 38564069
[No Abstract] [Full Text] [Related]
19. Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas - a single center experience with ten patients.
Lang H; Schlitt HJ; Schmidt H; Flemming P; Nashan B; Scheumann GF; Oldhafer KJ; Manns MP; Raab R
Langenbecks Arch Surg; 1999 Aug; 384(4):370-7. PubMed ID: 10473858
[TBL] [Abstract][Full Text] [Related]
20. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]